A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4+ T-cell recovery despite sustained virologic suppression: ACTG A5256
The Journal of Infectious Diseases, 07/05/2012
Wilkin TJ et al. – Adding maraviroc to suppressive ART for 24 weeks was not associated with an increase in CD4+ T–cell counts of at least 20 cells/uL. Further studies of CCR5 antagonists to dampen immune activation associated with HIV infection are warranted.
